American Society of Addiction Medicine

Addiction Medicine: Beyond the Abstract

American Society of Addiction Medicine

  • Relationship Between Methadone Induction Dosing and Retention in Treatment in Opioid Treatment Programs

Relationship Between Methadone Induction Dosing and Retention in Treatment in Opioid Treatment Programs

Thursday 28th August 2025

Explore methadone induction dosing's impact on retention in opioid treatment programmes with Dr. Sherrick's insights.
17 minutes
Informative
Educational
Engaging
Honest
Supportive

About this podcast

Addiction Medicine: Beyond the Abstract
Author:
American Society of Addiction Medicine
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Family Recovery from Addiction
Navigating Intimate Relationships
Nutritional Pathways to Recovery
Links:
Visit site
Episodes:
45 (View all)
Rounded Button Dark
Do you want to link to this podcast?
Get the buttons here!

Methadone Dosing: Balancing Retention and Risk

Episode Overview

  • Higher initial methadone doses may improve retention rates.
  • Observational studies show statistical associations but not causality.
  • New regulations allow starting at 50mg methadone doses.
  • Future research needed to balance dose effectiveness and safety.
  • Trends suggest experimenting with higher doses in inpatient settings.
"Higher doses at day seven were associated with better retention at day 30", says Dr. Sherrick.
In this episode of Addiction Medicine: Beyond the Abstract, Dr. Shawn McNeil sits down with Dr. Robert Sherrick to discuss the intriguing dynamics between methadone induction dosing and retention in opioid treatment programmes. Dr. Sherrick, a seasoned expert in addiction medicine, brings a wealth of experience from his role as Chief Science Officer at Community Medical Services. He sheds light on the challenges faced in methadone dosing, especially during the crucial first weeks of treatment.
Methadone, although a longstanding treatment option since the 1960s, still poses questions regarding optimal dosing strategies that could impact patient retention and safety. The conversation explores how varying methadone doses can influence patient outcomes and retention rates, sparking curiosity about whether higher initial doses might be beneficial or risky. Dr. Sherrick also highlights the limitations of observational studies and the need for more robust research to understand the delicate balance between effective treatment and potential risks.
As regulations evolve, the discussion touches on the potential for higher initial dosing under new guidelines, offering a glimpse into future directions for opioid treatment strategies. With anecdotes from his extensive career and insights into ongoing research, Dr. Sherrick provides valuable perspectives for clinicians and anyone interested in the intricacies of addiction treatment. If you're curious about how methadone dosing could shape the future of opioid treatment programmes, this episode is a must-listen.
alcoholfree.com
Published by The Mindful Drinking Company Limited
4 Providence Court, Pynes Hill, Exeter, Devon, EX2 5JL, England
Registered in England and Wales.
Company Number: 1195057. Vat Number: GB320915135.
Registered address as above.
© Copyright 2005-2025 The Mindful Drinking Company Limited.
All Rights Reserved.
alcoholfree.com is a participant in the Amazon Associates Programme, an affiliate advertising programme designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.co.uk. As an Amazon Associate, we earn from qualifying purchases.